BERLIN (GERMANY) – Europe’s drugs regulator said on Friday it had begun a real-time review of the COVID-19 vaccine, which is developed by German biopharmaceutical firm CureVac.
The European Medicines Agency said the decision by its human medicines committee to set out on the “rolling review” was determined from the vaccine’s preliminary results out of the laboratory studies and early clinical studies in adults.